0.392

1.04% -0.0041

After Hours: 1.76 1.368 +348.98%

BioCardia Inc. (BCDA)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

BioCardia Inc. stock is currently priced at $0.392, with a 24-hour trading volume of 64,959. It has seen a -1.04% decreased in the last 24 hours and a +6.49% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.4007 pivot point. If it approaches the $0.3915 support level, significant changes may occur.

Previous Close:

$0.3961

Open:

$0.398

24h Volume:

64,959

Market Cap:

$10.53M

Revenue:

$570.00K

Net Income/Loss:

$-12.53M

P/E Ratio:

-0.5851

EPS:

-0.67

Net Cash Flow:

$-11.13M

1W Performance:

-0.99%

1M Performance:

+6.49%

6M Performance:

-45.62%

1Y Performance:

-76.94%

1D Range:

$0.392

$0.40

52W Range:

$0.32

$2.9199

BioCardia Inc. Stock (BCDA) Company Profile

Name

BioCardia Inc.

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

650 226 0120

Address

320 Soquel Way, Sunnyvale, CA

Employee

Twitter

Next Earnings Date

2024-05-20

Latest SEC Filings

BCDA's Discussions on Twitter

BioCardia Inc. Stock (BCDA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

BioCardia Inc. Stock (BCDA) Latest News

Earnings call: BioCardia optimistic amid clinical trial progress and Japan strategy - Investing.com South Africa

Investing.com South Africa

Earnings call: BioCardia optimistic amid clinical trial progress and Japan strategy - Investing.com

Investing.com

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results - 14.05.2024 - wallstreet:online

wallstreet:online

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable - Simply Wall St

Simply Wall St

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable - Simply Wall St

Simply Wall St

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is ... - Yahoo Finance

Yahoo Finance

BioCardia Inc. Stock (BCDA) Financials Data

BioCardia Inc. (BCDA) Revenue 2024

BCDA reported a revenue (TTM) of $570.00 thousand for the quarter ending September 30, 2023, a -56.98% decline year-over-year.

BioCardia Inc. (BCDA) Net Income 2024

BCDA net income (TTM) was -$12.53 million for the quarter ending September 30, 2023, a -1.52% decrease year-over-year.

BioCardia Inc. (BCDA) Cash Flow 2024

BCDA recorded a free cash flow (TTM) of -$11.13 million for the quarter ending September 30, 2023, a -4.56% decrease year-over-year.

BioCardia Inc. (BCDA) Earnings per Share 2024

BCDA earnings per share (TTM) was -$0.62 for the quarter ending September 30, 2023, a +12.68% growth year-over-year.

BioCardia Inc. Stock (BCDA) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Altman Peter	President and CEO	Mar 28 '24	Buy	0.39	500	195	555,947
Altman Peter	President and CEO	Feb 13 '24	Buy	0.46	108,108	50,000	555,447
FROST PHILLIP MD ET AL	10% Owner	Jan 19 '24	Sale	0.43	129,802	55,815	1,896,025
Altman Peter	President and CEO	May 26 '23	Buy	1.60	6,200	9,920	469,239

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. has a collaboration agreement with CellProthera SAS to develop ProtheraCytes for the treatment of acute myocardial infarction. The company is based in Sunnyvale, California.